Clinical Report: Atsena Advances XLRS Gene Therapy
Overview
Atsena Therapeutics has initiated dosing in the Phase 3 LIGHTHOUSE trial for ATSN-201, a gene therapy targeting X-linked retinoschisis (XLRS). The trial aims to enroll 76 patients and evaluate the therapy's impact on retinal function over 52 weeks.
Background
X-linked retinoschisis (XLRS) is a rare inherited retinal disease primarily affecting males, leading to progressive vision loss and blindness. Currently, there are no approved treatments for XLRS.
Data Highlights
No numerical data available in the source material.
Key Findings
- The LIGHTHOUSE trial is a Phase 3 study evaluating ATSN-201 for XLRS.
- Enrollment began in May 2023 and has reached 10% of the target population.
- The trial will randomize participants to receive ATSN-201 or enter a control arm for 12 months.
- The primary endpoint is change in microperimetry at 52 weeks.
- Phase 1/2 data indicated that ATSN-201 could reverse structural retinal damage.
- A Biologics License Application is targeted for the second half of 2028.
Clinical Implications
The initiation of the LIGHTHOUSE trial highlights the urgent need for effective treatments for XLRS. As the trial progresses, it may provide valuable insights into the efficacy and safety of gene therapy in this patient population.
Conclusion
The advancement of ATSN-201 through clinical trials represents a potential breakthrough in the treatment of X-linked retinoschisis, addressing a significant unmet medical need.
Related Resources & Content
- Atsena Therapeutics, Ophthalmology Management, 2025 -- Atsena Therapeutics Granted Fast Track Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
- Atsena Therapeutics, The Ophthalmologist, 2026 -- Gene Therapy Reaches XLRS Milestone
- Atsena Therapeutics, Retinal Physician, 2025 -- Atsena Reports LIGHTHOUSE data at ARVO
- X-linked Retinoschisis - EyeWiki, 2023 -- X-linked Retinoschisis
- PMC, 2023 -- Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery
- New Retinal Physician — LIGHTHOUSE Trial for XLRS Gene Therapy Initiates Dosing of Second Cohort
- Atsena to Advance Pivotal Trial for X-Linked Retinoschisis
- X-linked Retinoschisis - EyeWiki
- Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
